A biopharmaceutical company, Syntiron is focused on the prevention and treatment of human disease resulting from bacterial infections. .Organized around developing innovative vaccines for humans, Syntiron's patented microbial antigen discovery and purification technology targets proteins that acquire iron, a critical nutrient that is required for survival of the bacteria. These proteins are expressed on the cell surface and are similar among different strains, making them ideal vaccine antigens. Syntironâs antigen discovery and purification technology targets the bacterial iron transport proteins that are critical for causing an infection. Building out from related work undertaken by others firm in the poultry and livestock space, Syntiron LLC took licenses from those players to apply those elements of that work towards developing microbial vaccines for humans. The firm's proprietary platform enables rapid identification of these proteins, which can then be directly extracted from the host cell or produced recombinantly for preclinical vaccine development.
